Interaction between bevacizumab and murine VEGF-A: a reassessment.
Volume: 49, Issue: 2, Pages: 522 - 527
Published: Feb 1, 2008
Abstract
Purpose null Bevacizumab is a humanized anti-human VEGF-A monoclonal antibody (mAb) approved by the United States Food and Drug Administration for cancer therapy and used off label to treat neovascular age-related macular degeneration. Earlier studies characterized bevacizumab as species specific and lacking the ability to neutralize murine (m) VEGF-A. However, a recent study reported that bevacizumab is a potent inhibitor of hemangiogenesis and...
Paper Details
Title
Interaction between bevacizumab and murine VEGF-A: a reassessment.
Published Date
Feb 1, 2008
Volume
49
Issue
2
Pages
522 - 527
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History